Skip to main content
Premium Trial:

Request an Annual Quote

Digene Signs Deal with Quest for Routine HPV DNA Testing

NEW YORK, Jan. 27 (GenomeWeb News) - Quest Diagnostics has agreed to market Digene's DNA-based test for human papillomavirus (HPV), Digene said today.

Under the three-year agreement, Quest will offer physicians Digene's HPV test for routine cervical cancer screening in conjunction with the Pap test.

Quest previously provided the test to physicians only for follow-up evaluation of ambiguous Pap test results. Digene's HPV test was approved in March 2003 for primary cervical cancer screening, in conjunction with a Pap test, in women age 30 and over.

The American College of Obstetricians and Gynecologists, the American Cancer Society, and the Association of Reproductive Health Professionals each have updated their screening guidelines to include HPV DNA testing as part of routine cervical cancer screening for women age 30 and older, Digene said.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.